Curium US Holdings LLC has entered into a definitive agreement to acquire Lantheus Holdings, Inc. for $102.50 per share in cash, with contingent rights worth up to an additional $12 per share if certain sales targets are met, bringing the total deal value to as much as $8 billion. The announcement was reported by Reuters on August 3, 2026.

The deal structure carries two distinct components. The upfront cash consideration of $102.50 per share is fixed at closing. Layered on top is a contingent value right (CVR) mechanism granting shareholders up to $12 per share in additional proceeds, contingent on Lantheus hitting specified sales benchmarks. CVRs are a common feature in pharma M&A, particularly when the target's pipeline or commercial trajectory has upside that the buyer is unwilling to pay for upfront but is willing to share post-close. They effectively transfer a portion of commercialization risk back to existing shareholders, who receive payment only if performance thresholds are met.

The trajectory from initial approach to signed agreement is notably compact. In May 2026, Reuters reported that Lantheus was weighing a potential sale after receiving a takeover offer from private-equity-backed Curium Pharma valued at approximately $7 billion. Roughly two and a half months later, the parties have landed on a definitive agreement at a headline figure that has expanded by roughly $1 billion, or about 14%, from that initial offer level.

The delta between the May figure and the August agreement reflects the negotiating dynamics between Curium and Lantheus. The increase from roughly $7 billion to up to $8 billion could reflect competitive tension in the auction process, improved commercial or pipeline visibility for Lantheus during the interim period, or simply the standard gap between an opening bid and a final agreed price. The CVR structure itself may have been the mechanism that bridged the valuation gap: by deferring up to $12 per share to contingent payments, Curium could offer a higher headline number while protecting its downside if Lantheus's revenue trajectory falls short.

The all-cash nature of the upfront consideration is notable for shareholders. Unlike stock-for-stock transactions, where exchange ratios expose investors to the acquirer's share price between signing and closing, a fixed cash price locks in the return (subject to deal completion risk). The contingency means the total return is not fully determined at signing; shareholders must weigh the probability of the sales targets being achieved when deciding whether to hold through closing or sell in the market at a discount to the blended headline value.

The transaction also requires standard regulatory approvals, including antitrust clearance, before it can close. No closing date has been specified in the reported materials.

Curium, backed by private equity, is executing an acquisitive strategy in the radiopharmaceutical space. Lantheus's portfolio in diagnostic and therapeutic radiopharmaceuticals aligns with a broader wave of dealmaking in the nuclear medicine segment, where targeted radioligand therapies have attracted substantial capital deployment from both strategic buyers and financial sponsors. The $8 billion ceiling on this transaction places it among the larger recent deals in the radiopharma sector.

For Lantheus shareholders, the key variables to monitor between now and closing are deal completion risk, the regulatory timeline, and, post-close, the specific sales thresholds attached to the CVR. The structure means that the realized value per share will range from $102.50 to $114.50 depending on commercial performance, and the market's trading price in the interim will reflect a probability-weighted blend of those outcomes adjusted for time value and deal risk.

The expansion from the initial $7 billion approach to the finalized up-to-$8 billion agreement over a roughly ten-week period is a useful data point on how quickly take-private processes can advance when both parties are motivated and the valuation gap is bridgeable through structured contingent payments. The use of a CVR to reconcile buyer and seller price expectations is a well-established template in life sciences M&A, and its deployment here follows that pattern closely.